Our Cloudbreak platform creates “single molecule cocktails” by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The resulting drug-Fc conjugate (DFC) immunotherapies are designed to inhibit specific disease targets while simultaneously engaging the immune system.